A Two-Pronged immune attack against HPV: could it prevent cervical cancer?
NCT ID NCT07735039
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests whether combining an oral immunomodulator with a vaginal ovule can help the body clear persistent high-risk human papillomavirus (HPV) infection, a key cause of cervical cancer. About 76 women with low-grade cervical changes will receive either the dual immunotherapy or standard supportive care for three months. The main goal is to see if the treatment leads to a negative HPV test afterward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an oral immunomodulator plus a vaginal ovule
- What this could lead to
- If effective, this dual immunotherapy could offer a non-surgical way to clear high-risk HPV and reduce the risk of cervical cancer.
- What could go wrong
- This is a small, early-stage trial with only 76 participants, so results may not apply broadly. The treatment may cause side effects or fail to improve HPV clearance over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Health Sciences Turkey, Kartal Dr. Lütfi Kırdar City Hospital
Istanbul, Istanbul, 34865, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A gel that could help the cervix heal from HPV?
- Simple vinegar test could rival High-Tech scope for cervical cancer screening
- Better swab, better catch: study aims to sharpen anal cancer screening
- HPV vaccine trial aims to protect women with HIV from cervical cancer
- New strategies help more teens get HPV vaccine
- Education boosts HPV vaccine willingness in women, study hopes